Lung Cancer
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
- Details
ClinicalTrials.gov ID:
NCT04819100
Diagnosis Type:
NA
USOR Number:
- Address
,
P: